|Table of Contents|

Correlation between autoimmune diseases and breast cancer risk based on Mendelian randomization method

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 21
Page:
4084-4089
Research Field:
Publishing date:

Info

Title:
Correlation between autoimmune diseases and breast cancer risk based on Mendelian randomization method
Author(s):
ZHAO Yaqi1; LIU Chunping2
1.Tongji Medical College,Huazhong University of Science and Technology,Hubei Wuhan 430030,China;2.Department of Breast and Thyroid Surgery,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei Wuhan 430022,China.
Keywords:
autoimmune diseases; Mendelian randomization; breast cancer; Crohn's disease
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2024.21.012
Abstract:
Objective:We used Mendelian randomization method for analysis in this study to explore the causal associations between various autoimmune diseases(Crohn's disease,psoriatic arthropathy,systemic lupus erythematosus,sacroiliitis) and the risk of breast cancer development.Methods:Tool variables were extracted from pooled data of genome-wide association studies.Autoimmune diseases were selected as exposure factors,while breast cancer was considered as the outcome factor.Single nucleotide polymorphisms(SNPs) that were clearly associated with the exposure factors were chosen as tool variables.The Egger-intercept method was employed to test for level heterogeneity,and sensitivity analysis was conducted using leave-one-out method.The inverse variance weighted method was utilized to evaluate the causal relationship between exposure and outcome.Results:The results from inverse variance weighted analysis indicated that Crohn's disease(OR=1.001,95%CI:1.000~1.002),psoriatic arthritis(OR=1.002,95%CI:1.001~1.005),and sacroiliitis(OR=1.001,95%CI:1.000~1.002) were identified as risk factors for breast cancer,whereas systemic lupus erythematosus(OR=0.999,95%CI:0.998~1.000) exhibited a protective effect against breast cancer development.CD39+ activated CD4+ regulatory T cells emerged as a primary mediating factor in establishing a causal link between Crohn's disease and breast cancer,accounting for 6% of the total mediation effect.Additionally,inflammatory markers such as C-reactive protein,P-selectin glycoprotein ligand 1,and IL-17B receptor were all found to be associated with an increased risk of developing breast cancer.Conclusion:Inflammation exacerbatesthe progression of breast cancer,thus suggesting that inflammation biomarkers may serve as valuable tools for monitoring disease progression and developing novel anti-inflammatory drugs aimed at preventing or treating breast cancer.

References:

［1］NGO ST,FJ STEYN,PA MCCOMBE.Gender differences in autoimmune disease［J］.Front Neuroendocrinol,2014，35(3):347-369.
［2］DEDOUSIS D,ANNIE L ZHANG,ANASTASIA N VASSILIOU,et al.Survival in elderly patients with breast cancer with and without autoimmune disease［J］.Cancer Med,2023,12(12):13086-13099.
［3］DEDOUSIS D,ANASTASIA N VASSILIOU,SHUFEN CAO,et al.Comparing survival in patients with lung cancer with and without a history of common autoimmune disease［J］.JTO Clin Res Rep,2022,3(9):100375.
［4］ZHOU SS,YU J.Crohn's disease and breast cancer:A literature review of the mechanisms and treatment［J］.Intern Emerg Med,2023,18(5):1303-1316.
［5］ALEXANDRA LADOUCEUR,ANN E CLARKE,ROSALIND RAMSEY-GOLDMAN,et al.Malignancies in systemic lupus erythematosus:An update［J］.Curr Opin Rheumatol,2019,31(6):678-681.
［6］SONG LB,WANG Y,ZHANG JY,et al.The risks of cancer development in systemic lupus erythematosus(SLE) patients:A systematic review and meta-analysis［J］.Arthritis Res Ther,2018,20(1):270.
［7］FARHAD ISLAMI,ANN GODING SAUER,KIMBERLY D MILLER,et al.Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States［J］.CA Cancer J Clin,2018,68(1):31-54.
［8］ANANTHAKRISHNAN AN,KHALILI H,KONIJETI GG,et al.Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease［J］.Gut,2014,63(5):776-784.
［9］LI N,SHI RH.Updated review on immune factors in pathogenesis of Crohn's disease［J］.World J Gastroenterol,2018,24(1):15-22.
［10］ZHOU J,YANG R.Identification of key pathways and genes shared between Crohn's disease and breast cancer using bioinformatics analysis［J］.Oncol Lett,2020,20(4):119.
［11］MS NNYLOR,GW STAMP,WD FOULKES,et al.Tumor necrosis factor and its receptors in human ovarian cancer.Potential role in disease progression［J］.J Clin Invest,1993,91(5):2194-2206.
［12］ASIEDU MK,INGLE JN,BEHRENS MD,et al.TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype［J］.Cancer Res,2011,71(13):4707-4719.
［13］TANG SW,HELMESTE DM,LEONARD BE.COVID-19 as a polymorphic inflammatory spectrum of diseases:A review with focus on the brain［J］.Acta Neuropsychiatr,2023,2023:1-22.
［14］ESMAILBEIG M,A GHADERI.Interleukin-18:A regulator of cancer and autoimmune diseases［J］.Eur Cytokine Netw,2017,28(4):127-140.
［15］ALINEJAD V,DOLATI S,MOTALLEBNEZHAD M,et al.The role of IL17B-IL17RB signaling pathway in breast cancer［J］.Biomed Pharmacother,2017,88:795-803.
［16］KROEGER PT JR,R DRAPKIN.Pathogenesis and heterogeneity of ovarian cancer［J］.Curr Opin Obstet Gynecol,2017,29(1):26-34.
［17］FREUER D,J LINSEISEN,C MEISINGER.Association between inflammatory bowel disease and both psoriasis and psoriatic arthritis:A bidirectional 2-sample mendelian randomization study［J］.JAMA Dermatol,2022,158(11):1262-1268.
［18］FREUER D,J LINSEISEN,C MEISINGER.Asthma and the risk of gastrointestinal disorders:A Mendelian randomization study［J］.BMC Med,2022,20(1):82.
［19］WU FS,HUANG Y,HU JL,et al.Mendelian randomization study of inflammatory bowel disease and bone mineral density［J］.BMC Med,2020,18(1):312.
［20］CARTER AR,SANDERSON E,HAMMERTON G,et al.Mendelian randomisation for mediation analysis:Current methods and challenges for implementation［J］.Eur J Epidemiol,2021,36(5):465-478.
［21］SHI Y,FENG SJ,YAN MD,et al.Inflammatory bowel disease and celiac disease:A bidirectional Mendelian randomization study［J］.Front Genet,2022,13:928944.
［22］SCHAIRER C,RM PFEIFFER,SM GADALLA.Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women［J］.Int J Cancer,2018,142(6):1202-1208.
［23］G RIEGLER,L CASERTA,F CASTIGLIONE,et al.Increased risk of breast cancer in first-degree relatives of Crohn's disease patients.An IG-IBD study［J］.Dig Liver Dis,2006,38(1):18-23.
［24］JOANA TORRES,SAURABH MEHANDRU,COLOMBEL JF,et al.Crohn's disease［J］.Lancet,2017,389(10080):1741-1755.
［25］NAKAJIMA H,A MUNAKATA,Y YOSHIDA.Extraintestinal cancers in Crohn's disease［J］.Digestion,1990,47(1):1-7.
［26］AGGARWAL BB.Nuclear factor-kappaB:The enemy within［J］.Cancer Cell,2004,6(3):203-208.
［27］AGGARWAL BB,RV VIJAYALEKSHMI,B SUNG.Targeting inflammatory pathways for prevention and therapy of cancer:Short-term friend,long-term foe［J］.Clin Cancer Res,2009,15(2):425-430.
［28］SINGH N,BABY D,RAIGURU JP,et al.nflammation and cancer［J］.Ann Afr Med,2019,18(3):121-126.
［29］LI HY，SHI XH，LI F,et al.Research progress on the relationship between inflammatory cytokines and symptom clusters of cancer patients［J］.Modern Oncology，2023，31（06）：1148-1152.
［30］DIGNASS A,G VAN ASSCHE,JO LINDSAY,et al.The second European evidence-based Consensus on the diagnosis and management of Crohn's disease:Current management［J］.J Crohns Colitis,2010,4(1):28-62.
［31］RAASCHOU P,T FRISELL,J ASKLING.TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis:A nationwide cohort study［J］.Ann Rheum Dis,2015,74(12):2137-2143.

Memo

Memo:
-
Last Update: 2024-09-30